Elanco (NYSE:ELAN) Surprises With Q4 CY2025 Sales

Elanco (NYSE:ELAN) Surprises With Q4 CY2025 Sales

Adam Hejl

Tue, February 24, 2026 at 8:38 PM GMT+9 6 min read

In this article:

ELAN

-0.92%

Animal health company Elanco (NYSE:ELAN) reported Q4 CY2025 results topping the market’s revenue expectations , with sales up 12.2% year on year to $1.14 billion. Guidance for next quarter’s revenue was better than expected at $1.29 billion at the midpoint, 1% above analysts’ estimates. Its non-GAAP profit of $0.13 per share was 15.6% above analysts’ consensus estimates.

Is now the time to buy Elanco? Find out in our full research report.

Elanco (ELAN) Q4 CY2025 Highlights:

**Revenue:** $1.14 billion vs analyst estimates of $1.09 billion (12.2% year-on-year growth, 4.8% beat)

**Adjusted EPS:** $0.13 vs analyst estimates of $0.11 (15.6% beat)

**Adjusted EBITDA:** $189 million vs analyst estimates of $178.1 million (16.5% margin, 6.1% beat)

**Revenue Guidance for Q1 CY2026** is $1.29 billion at the midpoint, above analyst estimates of $1.28 billion

**Adjusted EPS guidance for the upcoming financial year 2026** is $1.03 at the midpoint, in line with analyst estimates

**EBITDA guidance for the upcoming financial year 2026** is $970 million at the midpoint, below analyst estimates of $980.8 million

**Operating Margin:** 13.8%, up from 0.1% in the same quarter last year

**Constant Currency Revenue** rose 9% year on year (4% in the same quarter last year)

**Market Capitalization:** $12.3 billion

“Elanco delivered significant progress across our strategic priorities of growth, innovation, and cash in 2025,” said Jeff Simmons, President and CEO of Elanco.

Company Overview

Originally established as a division of pharmaceutical giant Eli Lilly before becoming independent in 2018, Elanco Animal Health (NYSE:ELAN) develops and sells medications, vaccines, and other health products for pets and farm animals across more than 90 countries.

Revenue Growth

A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Luckily, Elanco’s sales grew at a decent 7.6% compounded annual growth rate over the last five years. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.

Elanco Quarterly Revenue

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Elanco’s recent performance shows its demand has slowed as its annualized revenue growth of 3.3% over the last two years was below its five-year trend. We’re wary when companies in the sector see decelerations in revenue growth, as it could signal changing consumer tastes aided by low switching costs.

Story Continues  

Elanco Year-On-Year Revenue Growth

Elanco also reports sales performance excluding currency movements, which are outside the company’s control and not indicative of demand. Over the last two years, its constant currency sales averaged 5.5% year-on-year growth. Because this number is better than its normal revenue growth, we can see that foreign exchange rates have been a headwind for Elanco.

Elanco Constant Currency Revenue Growth

This quarter, Elanco reported year-on-year revenue growth of 12.2%, and its $1.14 billion of revenue exceeded Wall Street’s estimates by 4.8%. Company management is currently guiding for a 8.3% year-on-year increase in sales next quarter.

Looking further ahead, sell-side analysts expect revenue to grow 4.7% over the next 12 months, similar to its two-year rate. Although this projection implies its newer products and services will spur better top-line performance, it is still below the sector average.

Microsoft, Alphabet, Coca-Cola, Monster Beverage—all began as under-the-radar growth stories riding a massive trend. We’ve identified the next one: a profitable AI semiconductor play Wall Street is still overlooking. Go here for access to our full report.

Operating Margin

Although Elanco was profitable this quarter from an operational perspective, it’s generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 2.2% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It’s hard to trust that the business can endure a full cycle.

On the plus side, Elanco’s operating margin rose by 14.4 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company’s margin has increased by 26.6 percentage points on a two-year basis.

Elanco Trailing 12-Month Operating Margin (GAAP)

In Q4, Elanco generated an operating margin profit margin of 13.8%, up 13.7 percentage points year on year. This increase was a welcome development and shows it was more efficient.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Elanco’s EPS grew at an astounding 15.1% compounded annual growth rate over the last five years, higher than its 7.6% annualized revenue growth. This tells us the company became more profitable on a per-share basis as it expanded.

Elanco Trailing 12-Month EPS (Non-GAAP)

We can take a deeper look into Elanco’s earnings to better understand the drivers of its performance. As we mentioned earlier, Elanco’s operating margin expanded by 14.4 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its higher earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q4, Elanco reported adjusted EPS of $0.13, down from $0.14 in the same quarter last year. Despite falling year on year, this print easily cleared analysts’ estimates. Over the next 12 months, Wall Street expects Elanco’s full-year EPS of $0.95 to grow 7.6%.

Key Takeaways from Elanco’s Q4 Results

We enjoyed seeing Elanco beat analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. On the other hand, its EPS guidance for next quarter missed and its EBITDA guidance for next quarter fell short of Wall Street’s estimates. Zooming out, we think this was a mixed quarter. The market seemed to be hoping for more, and the stock traded down 1.4% to $24.41 immediately after reporting.

Is Elanco an attractive investment opportunity at the current price? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it’s free.

Terms and Privacy Policy

Privacy Dashboard

More Info